Inflammasome Priming in Sterile Inflammatory Disease

Trends in Molecular Medicine

Volumn 23, Issue 2, 2017, Pages 165-180

  Patel, Meghana N ^a   Carroll, Richard G ^a,b   Galván Peña, Silvia ^a,b   Mills, Evanna L ^a,b   Olden, Robin ^a,c   Triantafilou, Martha ^a,c   Wolf, Amaya I ^d   Bryant, Clare E ^a,e   Triantafilou, Kathy ^a,c   Masters, Seth L ^a,f,g  

^a GLAXOSMITHKLINE   (United Kingdom)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CRYOPYRIN; INFLAMMASOME; REACTIVE OXYGEN METABOLITE; INTERLEUKIN 1BETA; TOLL LIKE RECEPTOR;

ATHEROSCLEROSIS; AUTOINFLAMMATORY DISEASE; CHRONIC INFLAMMATION; COMPLEMENT SYSTEM; CROSS PRESENTATION; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INNATE IMMUNITY; LIPID METABOLISM; METABOLIC DISORDER; METABOLITE; MONOGENIC DISORDER; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; STERILE INFLAMMATORY DISEASE; TRANSCRIPTION REGULATION; UPREGULATION; ALZHEIMER DISEASE; ANIMAL; HEREDITARY PERIODIC FEVER; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION;

ALZHEIMER DISEASE; ANIMALS; ATHEROSCLEROSIS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; METABOLIC DISEASES; NEUROIMMUNOMODULATION; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; OBESITY; TOLL-LIKE RECEPTORS;

EID: 85009724396     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.12.007     Document Type: Review

References (156)

1. 1 Schroder, K., Tschopp, J., The inflammasomes. Cell 140 (2010), 821–832.
2. 2 Thornberry, N.A., et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356 (1992), 768–774.
3. 3 Hoffman, H.M., et al. Identification of a locus on chromosome 1q44 for familial cold urticaria. Am. J. Hum. Genet. 66 (2000), 1693–1698.
4. 4 Davis, B.K., et al. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 29 (2011), 707–735.
5. 5 Tschopp, J., Schroder, K., NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat. Rev. Immunol. 10 (2010), 210–215.
6. 6 Martinon, F., Detection of immune danger signals by NALP3. J. Leukoc. Biol. 83 (2008), 507–511.
7. 7 He, Y., et al. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 41 (2016), 1012–1021.
8. 8 Franchi, L., et al. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 13 (2012), 325–332.
9. 9 Bauernfeind, F.G., et al. NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183 (2009), 787–791.
10. 10 Bryant, C., Fitzgerald, K.A., Molecular mechanisms involved in inflammasome activation. Trends Cell Biol. 19 (2009), 455–464.
11. 11 Puren, A.J., et al. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 2256–2261.
12. 12 Zhou, R., et al. A role for mitochondria in NLRP3 inflammasome activation. Nature 469 (2011), 221–225.
13. 13 Zhou, R., et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11 (2010), 136–140.
14. 14 Shimada, K., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36 (2012), 401–414.
15. 15 Nakahira, K., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12 (2011), 222–230.
16. 16 Iyer, S.S., et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 39 (2013), 311–323.
17. 17 Ichinohe, T., et al. Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection. Proc. Natl. Acad. Sci. 110 (2013), 17963–17968.
18. 18 Bauernfeind, F., et al. Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 187 (2011), 613–617.
19. 19 Zheng, Q., et al. Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients. Exp. Eye Res. 134 (2015), 133–140.
20. 20 Folco, E.J., et al. Moderate hypoxia potentiates interleukin-1β production in activated human macrophages. Circ. Res. 115 (2014), 875–883.
21. 21 Iyer, S.S., et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. 106 (2009), 20388–20393.
22. 22 Ystgaard, M.B., et al. Early upregulation of NLRP3 in the brain of neonatal mice exposed to hypoxia–ischemia: no early neuroprotective effects of NLRP3 deficiency. Neonatology 108 (2015), 211–219.
23. 23 Panchanathan, R., Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation. Oncotarget 10 (2016), 28183–28194.
24. 24 Frede, S., et al. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κB. Biochem. J. 396 (2006), 517–527.
25. 25 Panchanathan, R., et al. Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation. Oncotarget 7 (2016), 28183–28194.
26. 26 Kim, E.-H., et al. Cobalt chloride-induced hypoxia ameliorates NLRP3-mediated caspase-1 activation in mixed glial cultures. Immune Netw. 13 (2013), 141–147.
27. 27 Miljkovi, D., et al. A comparative analysis of multiple sclerosis-relevant anti-inflammatory properties of ethyl pyruvate and dimethyl fumarate. J. Immunol. 194 (2015), 2493–2503.
28. 28 Wilms, H., et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation, 7, 2010, 30.
29. 29 Haas, B., et al. Permanent culture of macrophages at physiological oxygen attenuates the antioxidant and immunomodulatory properties of dimethyl fumarate. J. Cell. Physiol. 230 (2015), 1128–1138.
30. 30 Liu, X., et al. Dimethyl fumarate ameliorates dextran sulfate sodium-induced murine experimental colitis by activating Nrf2 and suppressing NLRP3 inflammasome activation. Biochem. Pharmacol. 112 (2016), 37–49.
31. 31 Masters, S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11 (2010), 897–904.
32. 32 Moon, J.-S., et al. mTORC1-unduced HK1-dependent glycolysis regulates NLRP3 inflammasome activation. Cell Rep. 12 (2015), 102–115.
33. 33 Tannahill, G.M., et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496 (2013), 238–242.
34. 34 Peng, H., et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J. Biol. Chem. 287 (2012), 28017–28026.
35. 35 Masters, S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11 (2010), 897–904.
36. 36 Lampropoulou, V., et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab. 24 (2016), 158–166.
37. 37 Li, Y., et al. Immune responsive gene 1 (IRG1) promotes endotoxin tolerance by increasing A20 expression in macrophages through reactive oxygen species. J. Biol. Chem. 288 (2013), 16225–16234.
38. 38 Duewell, P., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
39. 39 Wen, H., et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12 (2011), 408–415.
40. 40 Moon, J.-S., et al. UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis. J. Clin. Invest. 125 (2015), 665–680.
41. 41 Yokoyama, C., et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75 (1993), 187–197.
42. 42 Hua, X., et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 11603–11607.
43. 43 Ito, A., et al. LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. Elife, 4, 2015, e08009.
44. 44 Xiao, H., et al. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 128 (2013), 632–642.
45. 2+ fluxes leading to NLRP3 inflammasome activation. J. Cell Sci. 126 (2013), 2903–2913.
46. 46 Laudisi, F., et al. The NLRP3 inflammasome links complement-mediated inflammation and IL-1 release. J. Immunol. 191 (2013), 1006–1010.
47. 47 Fu, X., et al. Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice. Sci. Rep., 6, 2016, 30239.
48. 48 Suresh, R., et al. Complement-mediated ‘bystander’ damage initiates host NLRP3 inflammasome activation. J. Cell Sci. 129 (2016), 1928–1939.
49. 49 Haeffner-Cavaillon, N., C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J. Immunol. 139 (1987), 794–799.
50. 50 Asgari, E., et al. C3a modulates IL-1 secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 122 (2013), 3473–3481.
51. 51 Lajoie, S., et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat. Immunol. 11 (2010), 928–935.
52. 52 Duewell, P., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
53. 53 Pazar, B., et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1 secretion through the NLRP3 inflammasome in vitro. J. Immunol. 186 (2011), 2495–2502.
54. 54 Franklin, B.S., et al. Crystal formation in inflammation. Annu. Rev. Immunol. 34 (2016), 173–202.
55. 55 Samstad, E.O., et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 192 (2014), 2837–2845.
56. 56 An, L.-L., et al. Complement C5a potentiates uric acid crystal-induced IL-1β production. Eur. J. Immunol. 44 (2014), 3669–3679.
57. 57 Jiang, H., et al. Pertussis toxin-sensitive activation of phospholipase C by the C5a and fMet-Leu-Phe receptors. J. Biol. Chem. 271 (1996), 13430–13434.
58. 58 Mullmann, T.J., et al. Complement C5a activation of phospholipase D in human neutrophils: A major route to the production of phosphatidates and diglycerides. J. Immunol. 144 (1990), 1901–1908.
59. 59 Perianayagam, M.C., C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. Kidney Int. 61 (2002), 456–463.
60. 60 la Sala, A., et al. G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase–protein 3 kinase B/Akt pathway and JNK. J. Immunol. 175 (2005), 2994–2999.
61. 61 Buhl, A.M., et al. Mapping of the C5a receptor signal transduction network in human neutrophils. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 9190–9194.
62. 62 Ribas, C., et al. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim. Biophys. Acta 1768 (2007), 913–922.
63. 63 Brandstetter, C., et al. Complement component C5a primes retinal pigment epithelial cells for inflammasome activation by lipofuscin-mediated photooxidative damage. J. Biol. Chem. 290 (2015), 31189–31198.
64. 64 Haggadone, M.D., et al. Bidirectional crosstalk between C5a receptors and the NLRP3 inflammasome in macrophages and monocytes. Mediators Inflamm. 2016 (2016), 1–11.
65. 65 Juliana, C., et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J. Biol. Chem. 287 (2012), 36617–36622.
66. 66 Py, B.F., et al. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 49 (2013), 331–338.
67. 67 Lopez-Castejon, G., Deubiquitinases regulate the activity of caspase-1 and interleukin-1 secretion via assembly of the inflammasome. J. Biol. Chem. 288 (2013), 2721–2733.
68. 68 Gurung, P., et al. Chronic TLR stimulation controls NLRP3 inflammasome activation through IL-10 mediated regulation of NLRP3 expression and caspase-8 activation. Sci. Rep., 5, 2015, 14488.
69. 69 Filardy, A.A., et al. Posttranscriptional control of NLRP3 inflammasome activation in colonic macrophages. Mucosal Immunol. 9 (2016), 850–858.
70. 70 Ghonime, M.G., et al. Inflammasome priming by lipopolysaccharide Is dependent upon ERK signaling and proteasome function. J. Immunol. 192 (2014), 3881–3888.
71. 71 Fernandes-Alnemri, T., TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome. J. Immunol. 191 (2013), 3995–3999.
72. 72 O'Neill, L.A.J., Pearce, E.J., Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 213 (2016), 15–23.
73. 73 Vance, R.E., Inflammasome activation: how macrophages watch what they eat. Cell Host Microbe 7 (2010), 3–5.
74. 74 Szabo, G., Csak, T., Inflammasomes in liver diseases. J. Hepatol. 57 (2012), 642–654.
75. 75 Vandanmagsar, B., et al. The NALP3/NLRP3 inflammasome instigates obesity-induced autoinflammation and insulin resistance. Nat. Med. 17 (2011), 179–188.
76. 76 Holvoet, P., et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53 (2004), 1068–1073.
77. 77 Holvoet, P., et al. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 194 (2007), 245–252.
78. 78 Holvoet, P., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 21 (2001), 844–848.
79. 79 Lapointe, A., et al. Circulating oxidized LDL is associated with parameters of the metabolic syndrome in postmenopausal women. Atherosclerosis 191 (2007), 362–368.
80. 80 Couillard, C., et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J. Clin. Endocrinol. Metab. 90 (2005), 6454–6459.
81. 81 Ho, R.C., et al. Whole-body insulin sensitivity, low-density lipoprotein (LDL) particle size, and oxidized LDL in overweight, nondiabetic men. Metabolism 51 (2002), 1478–1483.
82. 82 Sheedy, F.J., et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14 (2013), 812–820.
83. 83 Patel, M.N., et al. Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 506–511.
84. 84 Barath, P., et al. Detection and localization of tumor necrosis factor in human atheroma. Am. J. Cardiol. 65 (1990), 297–302.
85. 85 Nixon Tangi, T., et al. Role of NLRP3 and CARD8 in the regulation of TNF-α induced IL-1β release in vascular smooth muscle cells. Int. J. Mol. Med. 30 (2012), 697–702.
86. 86 Franchi, L., et al. TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J. Immunol. 183 (2009), 792–796.
87. 87 Lumeng, C.N., et al. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117 (2007), 175–184.
88. 88 Kwon, H., Pessin, J.E., Adipokines mediate inflammation and insulin resistance. Front. Endocrinol., 4, 2013, 71.
89. 89 Lagathu, C., et al. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 49 (2006), 2162–2173.
90. 90 Jager, J., et al. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148 (2007), 241–251.
91. 91 Hiscott, J., et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 13 (1993), 6231–6240.
92. 92 Bauernfeind, F., et al. Aging-associated TNF production primes inflammasome activation and NLRP3-related metabolic disturbances. J. Immunol. 197 (2016), 2900–2908.
93. 93 Stienstra, R., et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 15324–15329.
94. 94 Lee, H.-M., et al. Upregulated NLRP3 inflammasome Activation in patients with type 2 diabetes. Diabetes 62 (2013), 194–204.
95. 95 Unger, R.H., et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim. Biophys. Acta 1801 (2010), 209–214.
96. 96 Demarchi, F., et al. Ceramide triggers an NF-κB-dependent survival pathway through calpain. Cell Death Differ. 12 (2005), 512–522.
97. 97 Robblee, M.M., et al. Saturated fatty acids engage an IRE1α-dependent pathway to activate the NLRP3 inflammasome in myeloid cells. Cell Rep. 14 (2016), 2611–2623.
98. 98 Reynolds, C.M., et al. Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol. Nutr. Food Res. 56 (2012), 1212–1222.
99. 99 Henao-Mejia, J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
100. 100 Wree, A., et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. 92 (2014), 1069–1082.
101. 101 Masters, S.L., O'Neill, L.A.J., Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol. Med. 17 (2011), 276–282.
102. 102 Heneka, M.T., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493 (2012), 674–678.
103. 103 Song, M., et al. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J. Neuroinflammation, 8, 2011, 92.
104. 104 Westwell-Roper, C.Y., Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1β production and β-cell dysfunction. Diabetes 63 (2014), 1698–1711.
105. 105 Westwell-Roper, C., Differential activation of innate immune pathways by distinct islet amyloid polypeptide (IAPP) aggregates. J. Biol. Chem. 291 (2016), 8908–8917.
106. 106 Alexiou, P., et al. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr. Med. Chem. 17 (2010), 2232–2252.
107. 107 Meissner, F., et al. Mutant superoxide dismutase 1-induced IL-1 accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. 107 (2010), 13046–13050.
108. 108 Tobisawa, S., et al. Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice. Biochem. Biophys. Res. Commun. 303 (2003), 496–503.
109. 109 Lebeaupin, C., et al. ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis., 6, 2015, e1879.
110. 110 Bronner, D.N., et al. Endoplasmic reticulum stress activates the inflammasome via NLRP3- and caspase-2-driven mitochondrial damage. Immunity 43 (2015), 451–462.
111. 111 Simard, J.-C., et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB1. PLoS One, 8, 2013, e72138.
112. 112 Frank, M.G., et al. The redox state of the alarmin HMGB1 is a pivotal factor in neuroinflammatory and microglial priming: a role for the NLRP3 inflammasome. Brain. Behav. Immun. 55 (2016), 215–224.
113. 113 Codolo, G., et al. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS One, 8, 2013, e55375.
114. 114 Agostini, L., et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20 (2004), 319–325.
115. 115 Nakamura, Y., et al. Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the Nlrp3 protein. Immunity 37 (2012), 85–95.
116. 116 Zhou, Q., et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat. Genet. 48 (2015), 67–73.
117. 117 Vande Walle, L., et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512 (2014), 69–73.
118. 118 Kayagaki, N., et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341 (2013), 1246–1249.
119. 119 Hagar, J.A., et al. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 341 (2013), 1250–1253.
120. 120 Shi, J., et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514 (2014), 187–192.
121. 121 Broz, P., et al. Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 490 (2012), 288–2891.
122. 122 Rathinam, V.A.K., TRIF kicenses caspase-11-dependent NLRP3 inflammasome activation by Gram-negative bacteria. Cell 150 (2012), 606–619.
123. 123 Gurung, P., et al. Toll or interleukin-1 receptor (TIR) domain-containing adaptor inducing interferon-β (TRIF)-mediated caspase-11 protease production integrates Toll-like receptor 4 (TLR4) protein- and Nlrp3 inflammasome-mediated host defense against enteropathogens. J. Biol. Chem. 287 (2012), 34474–34483.
124. 124 Aachoui, Y., et al. Caspase-11 protects against bacteria that escape the vacuole. Science 339 (2013), 975–978.
125. 125 Schauvliege, R., et al. Caspase-11 gene expression in response to lipopolysaccharide and interferon-gamma requires nuclear factor-kappa B and signal transducer and activator of transcription (STAT) 1. J. Biol. Chem. 277 (2002), 41624–41630.
126. 126 Man, S.M., et al. IRGB10 liberates bacterial ligands for sensing by the AIM2 and caspase-11–NLRP3 inflammasomes. Cell 167 (2016), 382–396.
127. 127 Lupfer, C.R., et al. Reactive oxygen species regulate caspase-11 expression and activation of the non-canonical NLRP3 inflammasome during enteric pathogen infection. PLoS Pathog., 10, 2014, e1004410.
128. 128 Napier, B.A., et al. Complement pathway amplifies caspase-11-dependent cell death and endotoxin-induced sepsis severity. J. Exp. Med. 213 (2016), 2365–2382.
129. 129 Gurung, P., et al. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J. Immunol. 192 (2014), 1835–1846.
130. 130 Günther, C., et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature 477 (2011), 335–339.
131. 131 Baker, P.J., et al. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur. J. Immunol. 45 (2015), 2918–2926.
132. 132 Heo, H., et al. Suppression of caspase-11 expression by histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 378 (2009), 79–83.
133. 133 Pituch, A., et al. Butyric acid in functional constipation. Gastroenterol. Rev. 5 (2013), 295–298.
134. 134 Zanoni, I., et al. An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science 352 (2016), 1232–1236.
135. 135 Morgan, B.P., Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 264 (1989), 1–14.
136. 136 Muller-Eberhard, H.J., The membrane attack complex of complement. Annu. Rev. Immunol. 4 (1986), 503–528.
137. 137 Morgan, B.P., The membrane attack complex as an inflammatory trigger. Immunobiology 221 (2016), 747–751.
138. 138 Gurung, P., Kanneganti, T.-D., Autoinflammatory skin disorders: the inflammasome in focus. Trends Mol. Med. 22 (2016), 545–564.
139. 139 Guo, H., et al. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21 (2015), 677–687.
140. 140 Shao, B.-Z., et al. NLRP3 inflammasome and its inhibitors: a review. Front. Pharmacol., 6, 2015, 262.
141. 141 Kuemmerle-Deschner, J.B., CAPS – pathogenesis, presentation and treatment of an autoinflammatory disease. Semin. Immunopathol. 37 (2015), 377–385.
142. 142 Doyle, S., et al. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J. Inflamm. Res. 8 (2015), 15–27.
143. 143 Li, Z., Rana, T.M., Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 13 (2014), 622–638.
144. 144 Christopher, A., et al. MicroRNA therapeutics: discovering novel targets and developing specific therapy. Perspect. Clin. Res., 7, 2016, 68.
145. 145 Bauernfeind, F., et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J. Immunol. 189 (2012), 4175–4181.
146. 146 Haneklaus, M., et al. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr. Opin. Immunol. 25 (2013), 40–45.
147. 147 Chen, S., Sun, B., Negative regulation of NLRP3 inflammasome signaling. Protein Cell 4 (2013), 251–258.
148. 148 Bandyopadhyay, S., MicroRNA-133a-1 regulates inflammasome activation through uncoupling protein-2. Biochem. Biophys. Res. Commun. 439 (2013), 407–412.
149. 149 Chen, S., et al. MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood 126 (2015), 103–112.
150. 150 Wang, W., et al. Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377. Free Radic. Biol. Med. 83 (2015), 214–226.
151. 151 Juliana, C., et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J. Biol. Chem. 287 (2012), 36617–36622.
152. 152 Hwang, I., et al. Histone deacetylase 6 negatively regulates NLRP3 inflammasome activation. Biochem. Biophys. Res. Commun. 467 (2015), 973–978.
153. 153 Deshaies, R.J., Protein degradation: prime time for PROTACs. Nat. Chem. Biol. 11 (2015), 634–635.
154. 154 Storek, K.M., Monack, D.M., Bacterial recognition pathways that lead to inflammasome activation. Immunol. Rev. 265 (2015), 112–129.
155. 155 Bezbradica, J.S., et al. Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals. Cell. Mol. Immunol. 14 (2017), 118–126.
156. 156 Kim, Y., et al. Suppression of NLRP3 inflammasome by γ-tocotrienol ameliorates type 2 diabetes. J. Lipid Res. 57 (2016), 66–76.